TABLE 3.
Clinical Signs and Demographic Features in NMDAR Antibody-Positive versus Antibody-Negative HSE Patients
| Sign/Feature | NMDAR Antibodies |
Probability | |
|---|---|---|---|
| Positive | Negative | ||
| Days between first clinical signs and admission |
6.3 ± 2.8 | 3.8 ± 2.2 | p < 0.05, Mann–Whitney U test |
| Neuropsychiatric/ neuropsychological symptomsa |
3/8 (38%) | 5/17 (29%) | NS, chi-square = 0.09, p = 0.76, chi-square test |
| Epileptic seizures | 2/8 (25%) | 2/17 (18%) | NS, chi-square = 0.49, p = 0.48, chi-square test |
| Gender | M 6/27 (25%), F 7/17 (41%) |
M 21/27 (75%), F 10/17 (59%) |
NS, chi-square = 1.80, p = 0.18, chi-square test |
| Age, yr | 53.0 ± 14.2 | 52.6 ± 17.5 | NS, p = 0.84, Mann–Whitney U test |
a
For example, confusion, amnestic deficits, behavioral changes.
F = female; HSE = herpes simplex encephalitis; M = male; NMDAR = N-methyl-d-aspartate receptor; NS = not significant.